

Amendments to the Specification:

Please amend Table 1 on page 14 of the application to reflect the new SEQ ID

Nos as follows:

Peptide PCP-	% Vasomotor response (of max constriction) ¹	% inhibition of maximal response	Peptide sequence	SEQ ID NO:
8	50.0	50.0	ilghrdyk	1
10	20.0	80.0	wedrfyll	2
14	36.0	64.0	YQDRFYLL	3
13	20.0	80.0	ILGHRDYK	[[1]]13
13.7	23.8	76.2	ILAHRDYK	4
13.8	46.8	53.2	IL _a HRDYK	[[4]]14
13.11	13.0	87.0	ILGFRDYK	5
13.13	36.9	63.1	ILGHKDYK	6
13.14	40.3	59.7	ILGHRNYK	7
13.18	30.0	70.0	ILGHQDYK	8
13.20	49.6	50.4	ILGHRDY-amide	9
13.21	46.2	53.8	ILGHRDYK-amide	[[1]]15
13.22	16.6	83.4	ILGWRDYK	10
13.24	6.2	93.8	ILGXRDYK	11
15	11.9	88.1	SNVLC SIF	12

Please amend the paragraphs beginning at page 4, line 32 through page 5, line 17 of the specification as follows:

Preferably, the antagonist include, without limitation, amino acid sequence of the FP receptor selected from the group consisting of ~~ILGHRDYK~~ ilghrdyk (PCP-8; SEQ ID NO:1); ~~WEDRFYLL~~ wedrfyll (PCP-10; SEQ ID NO:2); YQDRFYLL (PCP-14; SEQ ID NO:3); ILAHRDYK (PCP-13.7; SEQ ID NO:4); ILGFRDYK (PCP-13.11; SEQ ID NO:5); ILGHKDYK (PCP-13.13; SEQ ID NO:6); ILGHRNYK (PCP-13.14; SEQ ID NO:7);

Express Mail No.: EF 098985001 US

ILGHQDYK (PCP-13.18; SEQ ID NO:8); ILGHRDY-amide (PCP-13.20; SEQ ID NO:9); ILGHRDYK-amide (PCP-13.21; ~~SEQ ID NO:1~~ SEQ ID NO:15); ILGWRDYK (PCP-13.22; SEQ ID NO:10); ILGXRDYK (PCP-13.24; SEQ ID NO:11); SNVLCISF (PCP-15; SEQ ID NO:12) protein fusions and peptidomimetics thereof; wherein said amino acid sequence contains L- and/or D-amino acid.

In accordance with the present invention, there is provided a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 to ~~[[12]]~~15 and wherein said amino acid sequence contains L- and/or D-amino acid, an amino acid sequence with at least about 90% homology to SEQ ID NO: 1 to ~~[[12]]~~15, and peptidomimetic thereof.

Please insert two new paragraphs into the specification at page 7, line 23:

In accordance with another embodiment of the present invention, there is provided a prostaglandin F2 receptor antagonist consisting essentially of an amino acid sequence derived from the second extracellular loop of a prostaglandin F2 receptor, said amino acid sequence comprising one or more sequences selected from the group consisting of: ilghrdyk (PCP-8; SEQ ID NO:1); ILGHRDYK (PCP-13; SEQ ID NO:13); ILAHRDYK (PCP-13.7; SEQ ID NO:4); ILGFRDYK (PCP-13.11; SEQ ID NO:5); ILGHKDYK (PCP-13.13; SEQ ID NO:6); ILGHRNYK (PCP-13.14; SEQ ID NO:7); ILGHQDYK (PCP-13.18; SEQ ID NO:8); ILGHRDY-amide (PCP-13.20; SEQ ID NO:9); ILGHRDYK-amide (PCP-13.21; SEQ ID NO:15); ILGWRDYK (PCP-13.22; SEQ ID NO:10); ILAHRDYK (PCP-13.8; SEQ ID NO:14) and ILGXRDYK (PCP-13.24; SEQ ID NO :11), wherein X is cyclohexyl alanine, and wherein small letters indicate L-amino acids and capital letters indicate D-amino acids.

In accordance with another embodiment of the present invention, there is provided a peptide consisting essentially of a variant sequence of any one of SEQ ID NOs:1, 4 to 11, 13, 14 or 15 in which one or more amino acid residues are substituted or deleted, and wherein said variant sequence contains L- and/or D-amino acids and wherein said peptide is a prostaglandin F2 receptor antagonist.

Please also substitute the enclosed Substitute Sequence Listing with the originally filed Sequence Listing.

Express Mail No.: EF 098985001 US